234 results about "CD3 Antibody" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention relates to the technical field of nano-drug presentation systems, in particular to a TCR (T cell receptor) nano-vesicle antibody with both T cell redirection and immunosuppression reversal as well as a preparation method and application of the TCR nano-vesicle antibody. The TCR nano-vesicle antibody comprises a vesicle formed by a liposome and a cell membrane; tCR protein, a PD-1 antibody and a CD3 antibody are loaded on the vesicles. The nano vesicle antibody has the functions of T cell redirection and immunosuppression reversion; the difficulty of low stability of the soluble TCR is overcome; the polypeptide can be rapidly enriched in tumor tissues through tumor specificity TCR, and CD8 + T cells infiltrated by tumors are directly activated through an anti-CD3 antibody; depletion of T cells can be reversed through the PD-1 antibody on the surface, and the effector function of tumor infiltration CD8 + T cells is improved. The technical scheme can solve the technical problems that the TCR stability is not ideal and the immunosuppression state of the tumor microenvironment is difficult to overcome, and has ideal application and popularization prospects.

The invention relates to an antibody composition for detecting abnormal CTL (cytotoxic T lymphocyte) cells of hemophagocytic syndrome and application of the antibody composition, and the antibody composition comprises a CD2 antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD56 antibody, a CD57 antibody, a Granzyme B antibody, a Perforin antibody, a TRBC1 antibody and a CD45 antibody. In the technical scheme provided by the invention, key phenotypic characteristics of CTL (Cytotoxic Lymphocyte) can be completely covered by various antibodies aiming at T cell and NK cell surface markers, T large granular lymphocyte markers, cytotoxic granular proteins, T cell receptor constant regions and leukocyte common antigens; wherein the clonality of the CTL cells is judged through the expression level of the TRBC1 antibody, and the cytotoxic function activity of the CTL cells is evaluated through the expression levels of Granzyme B and Perforin.

Novel antibodies and antibody fragments that specifically bind CD3 and compositions containing the antibodies or antibody fragments. Nucleic acids encoding the antibodies or antibody fragments thereof and host cells containing the same, and related uses, and therapeutic and diagnostic uses of these antibodies and antibody fragments.

The present application provides antibodies comprising an antigen-binding fragment of an anti-CD3 antibody having tailor-made affinity to CD3 in low to medium range. In some embodiments, the antibody further comprises an antigen-binding fragment that specifically binds to a target antigen, such as HER2, CD20, TROP2, BCMA, or CD19. Also provided are anti-CD3 antibodies, masked anti-CD3 antibodies (including activatable anti-CD3 antibodies), anti-CD20 antibodies, and masked anti-HER2 antibodies (including activatable anti-HER2 antibodies). The antibodies described herein are useful for treatment of cancer.

The invention discloses a full-automatic multiplex fluorescent staining detection method for EBER, CD3 and CD20 and application of the full-automatic multiplex fluorescent staining detection method, and belongs to the technical field of biomarker detection. The invention relates to an EBER, CD3 and CD20 detection method, which comprises: carrying out digestion treatment on a sample to be detected, adding an EBER probe, and sequentially adding a primary antibody, a secondary antibody and a fluorescent dye A so as to complete color development; sequentially adding a CD3 antibody, an HRP polymer and a fluorescent dye B into the to-be-detected sample to finish CD3 dyeing; sequentially adding a CD20 antibody, an HRP polymer, a fluorescent dye C and a DAPI dye into a sample to be detected to finish CD20 dyeing; and observing or counting the dyeing result of the to-be-detected sample through fluorescence scanning equipment.

The present invention relates to humanized or chimeric CD3 antibodies. The present invention relates to humanized or chimeric antibodies that bind CD3. The invention further relates to bispecific antibodies, compositions, pharmaceutical compositions, uses of said antibodies in the treatment of disease and methods of treatment.

The invention discloses a bifunctional T cell adapter targeting CD14 and CD3 and an application of the bifunctional T cell adapter. Specifically, the invention provides a CD14 and CD3 targeting bifunctional T cell adapter, the CD14 and CD3 targeting bifunctional T cell adapter comprises a skeleton containing an IgG antibody constant region, the skeleton comprises two heavy chains and a light chain, one heavy chain comprises heavy chain constant regions CH1, CH2 and CH3, the other heavy chain comprises CH2 and CH3, the light chain comprises CL, the CD14 and CD3 targeting bifunctional T cell adapter is a heterotrimer, and the CD14 and CD3 targeting bifunctional T cell adapter is a heterotrimer. Specifically, the first subunit comprises a light chain variable region of an anti-CD14 antibody and a light chain in the skeleton, the second subunit comprises a heavy chain variable region of the anti-CD14 antibody and a heavy chain in the skeleton, and the third subunit comprises a heavy chain variable region of an anti-CD3 antibody and a light chain variable region. The bifunctional T cell adapter disclosed by the invention has an excellent tumor killing effect.

The invention discloses a spleen-targeted nano platform construction method suitable for tumor vaccination, and particularly relates to the field of vaccines.The spleen-targeted nano platform construction method comprises the steps that S1, CL15H6-DOPS LNPs, spherical polymer vesicles and erythrocyte membrane coated nano-particles are selected as spleen-targeted nano-carriers; s2, integrating an immunologic adjuvant; mn < 2 + > doped LNPs, ultrasonic response lipidosome and a CD3 antibody are selected to be coupled to serve as an integration material; s3, delivering in vivo; animal models are selected for in-vivo delivery and curative effect verification, and B16F10 melanoma mice, MC38 colon cancer mice and non-human primates are selected as the animal models respectively. By optimizing the chain length and the surface topological structure (such as spherical polymer vesicles) of the liposome, the spleen enrichment rate is remarkably increased, and the red marrow myeloid cell uptake efficiency is enhanced. By combining with common delivery of a manganese adjuvant, an STING channel is activated, secretion of type I interferon is promoted, and the proportion of antigen-specific CD8 + T cells and the tumor inhibition rate are increased.

The present application relates to an anti-CD3 antibody and its application. The present application develops a specific antibody molecule targeting CD3 epsilon chain, which can activate T cells by combining with CD3 epsilon on T cells. A T cell binding protein containing the CD3 antibody is further designed, which can specifically target and bind to CD3 epsilon on the surface of T cells in vivo and in vitro, so as to achieve moderate activation of T cells. The CAR lentivirus containing the T cell binding protein of the present application can induce the generation of CAR-T cells in vitro and in vivo, and the CAR-T cells have good tumor cell killing efficiency.

The application discloses an antibody targeting DLL3 and application thereof, and relates to the field of biological medicines. Specific anti-DLL3 nanobodies are screened in the embodiment of the application, and a bispecific antibody constructed from the anti-human DLL3 nanobody or humanized nanobody and an anti-human CD3 antibody is prepared, the obtained bispecific antibody has good antitumor activity, can be applied to preparation of at least one drug for preventing or treating a DLL3 expression abnormality related tumor or cancer disease including small cell lung cancer, and has wide application.

The present disclosure provides anti-CD3 monoclonal antibodies and related compositions, which can be used in any of a variety of therapeutic and diagnostic methods for the treatment of diseases and disorders, such as cancer and autoimmune diseases and disorders. The present disclosure also relates to bispecific antibodies comprising anti-CD3 antibodies. The present disclosure further relates to methods of treatment using such anti-CD3 monoclonal and bispecific antibodies. The present disclosure generally relates to anti-CD3 antibodies, compositions and methods using same.

The application belongs to the technical field of biological medicine, and discloses an in-situ vaccine type mRNA-tLNP preparation for solid tumor treatment and preparation and application thereof. The preparation is designed by double targets, so that CAR-T kills more tumor cells to overcome tumor heterogeneity, changes the tumor immune microenvironment through autocrine fusion proteins (anti-PD-1 scFv and TGFbetaRII, IL-15 and Flt3L, CD40L), promotes T cell proliferation, and recruits and activates dendritic cells, cross-presents new antigens in the tumor local part, and produces in-situ vaccination effects; circular RNA encoding the above proteins is prepared, and the circular RNA is wrapped by lipid nanoparticles modified by CD3 antibodies, so as to be directly delivered to the body, and a significant solid tumor treatment effect is produced.

The invention relates to a human peripheral blood cell immunotyping antibody combination and method based on flow cytometry. The antibody combination comprises an anti-CD3 antibody, an anti-CD4 antibody, an anti-CD8 antibody, an anti-EGFR antibody, an anti-CD25 antibody, an anti-CD127 antibody, an anti-CD45RA antibody, an anti-CCR7 antibody, an anti-CD27 antibody, an anti-PD-1 antibody, an antiTIGIT antibody and an anti-41BB antibody. The method comprises the following steps: mixing the antibody combination with a sample to be detected, incubating, performing flow cytometry detection to obtain detection data, and further judging the proportion and / or the number of target cell populations. According to the present invention, the optimal cell surface marker antibody combination is designed and obtained, the CAR-T cells in the sample are subjected to immune typing by using the 12-color antibody combination through the flow cytometry, the detection result is rapidly obtained, the CAR-T cell proportion of each phenotype is efficiently identified, and the method has high precision and high stability.

Antibodies and antigen-binding fragments thereof having high affinity for CD3 and desirable developability profiles are provided, as are methods for making and using the same.

The present disclosure provides anti-commensal antibody (ACAb)-based profiles and methods of selecting a subject at risk of developing type 1 diabetes (T1D) for treatment with an anti-CD3 antibody. Also provided is a method of treating a subject at risk of developing T1D with an anti-CD3 antibody when the subject has an ACAb-based profile that predicts the subject is a responder the treatment. Further provided are ACAb-based profiles and methods of predicting that a subject at risk of developing T1D will progress to T1D.

The invention provides an antibody capable of specifically binding CD3 protein or an antigen binding fragment thereof, and a multispecific antibody containing the anti-CD3 antibody or the antigen binding fragment thereof. The present application also provides multispecific antibodies, pharmaceutical compositions, methods of making and using the antibodies or antigen binding fragments thereof, or uses of the multispecific antibodies in the manufacture of medicaments for the treatment of cancer.

The invention provides a fusion protein based on a GLP-1 analogue, a T cell therapeutic drug and an application of the fusion protein and the T cell therapeutic drug in tumor resistance, and relates to the field of preparation of antibodies and cell therapeutic drugs. The fusion protein based on the GLP-1 analogue is obtained by fusing a T cell activation antibody and the GLP-1 analogue, the T cell activation antibody is a BiTE antibody, the BiTE antibody is a CD3 / EpCAM fusion antibody, and the GLP-1 analogue is dulaglycopeptide; the CD3 / EpCAM fusion antibody is composed of a light chain and a heavy chain of a CD3 antibody and a light chain and a heavy chain of an EpCAM antibody, wherein the heavy chain of the CD3 antibody and the heavy chain of the EpCAM antibody are connected through a peptide linker; the C end of the dulatide is fused with the N end of the light chain of the CD3 antibody, and the middle is connected with the N end through a peptide joint; the obtained fusion protein based on the GLP-1 analogue can be used for preparing anti-tumor drugs and T cell treatment drugs, and has the effects of reducing toxicity and enhancing efficacy.

The present invention relates to preparations containing anti-CLDN18.2 / CD3 antibody, in particular to pharmaceutical preparations comprising an anti-CLDN18.2 / CD3 antibody, a buffer, a stabilizer and a surfactant. In addition, the present invention also relates to the use of the preparations in disease treatment or prevention.

A platform for therapy provides a multi-target therapeutic molecule comprising an anti-CD3 antigen binding fragment of an anti-CD3 antibody linked with a linker to two or more auto-antigen(s). The auto-antigens include Dsg1, Dsg3, bullous pemphigoid antigen 180, bullous pemphigoid antigen 230, MuSK, anti-phospholipase A2 Receptor. A pharmaceutical composition comprises a disclosed multi-target therapeutic molecule is disclosed. Methods of treating diseases using the disclosed molecules are disclosed

The invention discloses a pharmaceutical composition and application thereof, the pharmaceutical composition comprises a recombinant protein and an HIV virus invasion inhibitor, and the recombinant protein comprises: 1) an scFV of an anti-CD3 antibody; and 2) diphtheria toxin.

The invention discloses a recombinant oncolytic influenza virus for delivering an anti-gpA33 * CD3 bispecific antibody and application of the recombinant oncolytic influenza virus. Belongs to the technical field of biological medicine. According to the recombinant oncolytic influenza virus provided by the invention, a heavy chain variable region and a light chain variable region of an anti-gpA33 antibody and an anti-CD3 antibody are inserted into an influenza virus genome, the recombinant oncolytic influenza virus is rescued through a reverse genetics technology, and the virus can stably express an anti-gpA33 * CD3 bispecific antibody in colorectal cancer cells; one end of the antibody can be specifically combined with CD3 molecules on the surfaces of the T cells to efficiently activate the T cells, the other end of the antibody can be specifically combined with biomarker molecules gpA33 on the surfaces of the colorectal cancer cells, and under the bridging action of the antibody, the activated T cells are collected to the surfaces of the colorectal cancer cells to induce the T cells to directly generate the effect of targeted killing of the colorectal cancer cells, so that the colorectal cancer cells are efficiently killed. Therefore, the purpose of treating tumors is achieved.

This invention relates to the selective removal of activated T cells using a monovalent antibody or its antigen-binding fragment, which includes heavy chain variable regions and light chain variable regions of an antibody that specifically binds to CD3. In one embodiment of the present invention, the monovalent anti-CD3 antibody or its antigen-binding fragment is useful as a T cell removal agent or T cell immunosuppressant because it can selectively remove only activated T cells without affecting non-activated T cells. In particular, this invention is useful for the prevention or treatment of T cell-mediated autoimmune diseases, graft-versus-host diseases, or organ transplant rejection, as well as for the prevention of graft-versus-host disease (GVHD) side effects in allogeneic CAR-T cell therapy.

The invention discloses a CD8 + T cell culture solution and application thereof. The cell culture solution comprises an induction culture solution and an amplification culture solution, wherein the amplification culture solution comprises a basic culture medium, and the basic culture medium contains ginsenoside with the final concentration of 20-100 [mu] g / mL, concanavalin A with the final concentration of 20-100 [mu] g / mL and IL-2 with the final concentration of 100-1000 U / mL; the induction culture solution is based on an amplification culture medium, and a CD3 antibody with the final concentration of 50-100 ng / mL and a CD28 antibody with the final concentration of 50-100 ng / mL are added. The ginsenoside component in the CD8 + T cell culture fluid can induce and stimulate PBMC to be differentiated into CD8 + T cells, and concanavalin A cooperates with ginsenoside to promote rapid amplification and growth of the CD8 + T cells; meanwhile, the cell culture method is simple to operate and low in cost, and has certain universality.

The present disclosure provides methods of treating a SMARCB1-deficient cancer. In certain embodiments, the methods comprise administering an anti-MUC16 / anti-CD3 antibody or antigen-binding fragment thereof to a subject in need thereof. In certain embodiments, the methods further comprise administering a PD-1 inhibitor (e.g., an anti-PD-1 antibody) or a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody) to the subject in need thereof.

The present invention provides methods of treating and preventing symptoms of coronavirus infection using antibodies that recognize CD3. The present invention further provides routes of administration and formulations for use in the methods.

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

The invention discloses a nano drug delivery system for targeting immune cells. Comprising core nanoparticles formed by a polylactic acid-glycolic acid copolymer and used for encapsulating a therapeutic drug; the polyethylene glycol functional layer is coated on the surface of the core, so that the blood circulation time is prolonged; the targeting ligand is covalently connected to the polyethylene glycol layer, is a high-affinity ligand for specifically recognizing an immune cell surface receptor, and comprises an anti-DEC205 single-chain antibody fragment and a mannose or anti-CD3 antibody fragment. The innovation point is that the binding affinity of the targeting ligand to specific receptors on the surfaces of dendritic cells, macrophages or T cells is obviously higher than that of a conventional ligand, and efficient intracellular delivery is realized through a synergistic structure of a polylactic acid-glycolic acid copolymer-polyethylene glycol-ligand. The technical effects comprise that the in-vitro target immune cell uptake efficiency is greatly improved, the tumor tissue drug enrichment degree of a tumor-bearing mouse is multiplied compared with that of a non-targeted carrier, and the antigen presentation and T cell activation capability is remarkably enhanced.